Vitrolife AB
STO:VITR

Watchlist Manager
Vitrolife AB Logo
Vitrolife AB
STO:VITR
Watchlist
Price: 221.4 SEK 4.04% Market Closed
Market Cap: 30B SEK
Have any thoughts about
Vitrolife AB?
Write Note

Vitrolife AB
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Vitrolife AB
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Vitrolife AB
STO:VITR
Long-Term Debt
kr1.9B
CAGR 3-Years
230%
CAGR 5-Years
97%
CAGR 10-Years
67%
Biogaia AB
STO:BIOG B
Long-Term Debt
kr0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Long-Term Debt
kr8.5m
CAGR 3-Years
17%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Probi AB
STO:PROB
Long-Term Debt
kr68.2m
CAGR 3-Years
14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Long-Term Debt
kr11.7B
CAGR 3-Years
7%
CAGR 5-Years
5%
CAGR 10-Years
31%
BioArctic AB
STO:BIOA B
Long-Term Debt
kr2.2m
CAGR 3-Years
-46%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Vitrolife AB
Glance View

Market Cap
30B SEK
Industry
Biotechnology

Vitrolife AB engages in the development, manufacture, and sale of products and systems for the preparation, cultivation, and storage of human cells, tissue, and organs. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 427 full-time employees. The company went IPO on 2001-06-26. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. The company also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The firm is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.

VITR Intrinsic Value
139.61 SEK
Overvaluation 37%
Intrinsic Value
Price

See Also

What is Vitrolife AB's Long-Term Debt?
Long-Term Debt
1.9B SEK

Based on the financial report for Sep 30, 2024, Vitrolife AB's Long-Term Debt amounts to 1.9B SEK.

What is Vitrolife AB's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
67%

Over the last year, the Long-Term Debt growth was -6%. The average annual Long-Term Debt growth rates for Vitrolife AB have been 230% over the past three years , 97% over the past five years , and 67% over the past ten years .

Back to Top